These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 28503960)

  • 41. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.
    Leccese P; Latanza L; D'Angelo S; Padula A; Olivieri I
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S93. PubMed ID: 21813069
    [No Abstract]   [Full Text] [Related]  

  • 42. Behçet's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis.
    Adler S; Baumgartner I; Villiger PM
    Arthritis Care Res (Hoboken); 2012 Apr; 64(4):607-11. PubMed ID: 22162223
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab.
    Barešić M; Reihl M; Habek M; Vukojević N; Anić B
    Rheumatol Int; 2018 Jul; 38(7):1301-1306. PubMed ID: 29777341
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
    Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
    Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnosis and management of intestinal Behçet's disease.
    Hisamatsu T; Naganuma M; Matsuoka K; Kanai T
    Clin J Gastroenterol; 2014 Jun; 7(3):205-12. PubMed ID: 24883128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adalimumab in the treatment of pediatric Behçet's disease: case-based review.
    Poddighe D; Mukusheva Z; Dauyey K; Assylbekova M
    Rheumatol Int; 2019 Jun; 39(6):1107-1112. PubMed ID: 30976833
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Behçet's disease: New insights into pathophysiology, clinical features and treatment options.
    Greco A; De Virgilio A; Ralli M; Ciofalo A; Mancini P; Attanasio G; de Vincentiis M; Lambiase A
    Autoimmun Rev; 2018 Jun; 17(6):567-575. PubMed ID: 29631062
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study.
    Fabiani C; Sota J; Vitale A; Rigante D; Emmi G; Vannozzi L; Bacherini D; Lopalco G; Guerriero S; Gentileschi S; Capozzoli M; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Br J Ophthalmol; 2018 May; 102(5):637-641. PubMed ID: 28844047
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
    Fabiani C; Vitale A; Emmi G; Vannozzi L; Lopalco G; Guerriero S; Orlando I; Franceschini R; Bacherini D; Cimino L; Soriano A; Frediani B; Galeazzi M; Iannone F; Tosi GM; Salvarani C; Cantarini L
    Clin Rheumatol; 2017 Jan; 36(1):183-189. PubMed ID: 27853889
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.
    Handa T; Tsunekawa H; Yoneda M; Watanabe D; Mukai T; Yamamura M; Iwaki M; Zako M
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S58-63. PubMed ID: 21968238
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successful use of infliximab in a patient with neuro-Behçet's disease.
    Abalos-Medina GM; Sánchez-Cano D; Ruiz-Villaverde G; Ruiz-Villaverde R; Quirosa Flores S; Raya Alvarez E
    Int J Rheum Dis; 2009 Sep; 12(3):264-6. PubMed ID: 20374357
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis.
    Takase K; Ohno S; Ideguchi H; Uchio E; Takeno M; Ishigatsubo Y
    Rheumatol Int; 2011 Feb; 31(2):243-5. PubMed ID: 19816689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment with Biologic Drugs in Pediatric Behçet's Disease: A Comprehensive Analysis of the Published Data.
    Batu ED; Sener S; Cam V; Aktay Ayaz N; Ozen S
    BioDrugs; 2023 Nov; 37(6):813-828. PubMed ID: 37382804
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment.
    Sfikakis PP; Arida A; Panopoulos S; Fragiadaki K; Pentazos G; Laskari K; Tektonidou M; Markomichelakis N
    Arthritis Rheumatol; 2017 Dec; 69(12):2380-2385. PubMed ID: 28834393
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
    Interlandi E; Leccese P; Olivieri I; Latanza L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expert opinion on the use of biological therapy in non-infectious uveitis.
    Touhami S; Diwo E; Sève P; Trad S; Bielefeld P; Sène D; Abad S; Brézin A; Quartier P; Koné Paut I; Weber M; Chiquet C; Errera MH; Sellam J; Cacoub P; Kaplanski G; Kodjikian L; Bodaghi B; Saadoun D
    Expert Opin Biol Ther; 2019 May; 19(5):477-490. PubMed ID: 30888881
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
    Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
    Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Behçet's disease.
    Karube H; Kamoi K; Ohno-Matsui K
    Int Med Case Rep J; 2016; 9():301-304. PubMed ID: 27729816
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Resolution of Behçet's syndrome associated pulmonary arterial aneurysms with infliximab.
    Schreiber BE; Noor N; Juli CF; Haskard DO
    Semin Arthritis Rheum; 2011 Dec; 41(3):482-7. PubMed ID: 21546064
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab.
    Zou J; Ji DN; Cai JF; Guan JL; Bao ZJ
    Dig Dis Sci; 2017 Feb; 62(2):441-447. PubMed ID: 28044230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.